(Q36388327)

13 August 2017

1 reference

title

The concept of hepatitis B virus mutant escape (English)

1 reference

13 August 2017

1 reference

1 reference

Jean-Michel Pawlotsky

series ordinal

1

object named as

Jean-Michel Pawlotsky

0 references

author name string

Jean-Michel Pawlotsky

series ordinal

1

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Journal of Clinical Virology

13 August 2017

published in

1 reference

13 August 2017

volume

34 Suppl 1

1 reference

13 August 2017

page(s)

S125-9

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

The clinical significance of surface antigen variants of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

1 reference

7 January 2021

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

A long-term follow-up analysis of serial core promoter and precore sequences in Japanese patients chronically infected by hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Kinetics of acute hepatitis B virus infection in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2805%2980021-6

7 January 2021

10.1016/S1386-6532(05)80021-6

Identifiers

DOI

1 reference

13 August 2017

1 reference